The use of stem cells in medicine began in 1968, and the world's first bone marrow transplant successfully treated a patient with severe combined immunodeficiency. In recent years, the state has vigorously advocated the development of stem cell technology. In October 2016, the “Healthy China 2030 Plan†proposed the development of omics technology, stem cell and regenerative medicine, new vaccines, biotherapy and other medical frontier technologies; in 2017, the National Health The Planning Commission, the National Development and Reform Commission, the Ministry of Science and Technology, and the Food and Drug Administration issued a number of documents on stem cell research, transformation, and clinical research.
In China, the stem cell industry chain has also been developed from the upstream collection and storage to the downstream research on stem cell new drug development, medical beauty, and anti-aging. However, due to lack of product and technology innovation capabilities, long return period and insufficient social capital, this has hindered the development of the stem cell industry to some extent.
Since its inception in 2012, 舜喜å†ç”ŸåŒ»å¦ has been committed to solving the health problems in traditional medical fields with high-tech biotechnology. Arterial Network interviewed Jiang Xiaofeng, general manager of Yunnan Xixi Regenerative Medicine. "By the stem cell technology of Monash University in Australia, I will cooperate with many top three hospitals in China to treat immune diseases, solid tumors and lungs. Research in the fields of fibrosis and anti-aging of medical beauty, and the evaluation of the safety and effectiveness of the stem cell application medical market, most of which are currently in clinical trials."
Yixi Regenerative Medicine is the first founding member of the Global Cord Blood Alliance in China. It has 3 invention patents, 9 utility models, and 1 soft one. It was recognized by the national high-tech enterprise in 2016.
With technology to benefit all beings, capital helps 舜 快速 fast start
The Qixi Group was founded in 2012, when stem cell research was under the control of the government in China, and the company's development was difficult.
So, Xixi turned his eyes to foreign countries. They found the most advanced stem cell research team in the Southern Hemisphere, the Stem Cell Research Center of Monash University in Australia, and integrated this excellent team through investment and shareholding to establish a whole layer in Australia. Yuxi-Monash Immunoassay and Neuroscience Laboratory. This is the first time Monash University has cooperated with Chinese companies, and Xixi has become the only authorized global industrialization of stem cell technology in Monash University except Australia.
Professor Alan Trounson of Monash University is the chief scientist of the company. In 2013, he was named one of the world's ten most influential scientists in the field of stem cells, and managed $3 billion in research funding for stem cell research. The team of scientists also includes Professor Richard Boyd, Professor Emeritus of Beijing 301 Hospital, Professor Emeritus of the University of Tokushima, Japan, and internationally renowned for immunology and stem cell research.
In 2012, Shanghai Mei Nian and Shenyang Health merged to form the Midea Health Industry Group. Subsequently, Xixi Strategy joined the Shanghai Mei Nian Health, and both sides made a hit for the development of the health industry to jointly develop a healthy market.
At that time, the two sides found through research that the development of the medical examination industry in Yunnan area was almost blank. In view of this business opportunity, the two sides established the first flagship store in Yunnan with the largest beauty in the past, with a store area of ​​up to 5,000. Multi-square meters, and the introduction of high-end medical equipment such as capsule gastroscope, nuclear magnetic, CT, etc., is committed to providing first-class service to users through a first-class team. Since then, Yuxi has established an industrial fund, specializing in investing in the US health and beauty platform, and has become one of the core shareholders of the United States.
Yixi Regenerative Medical Technology Team
“Yunnan’s beauty and health flagship store has been widely favored by users and has become the vane of the development of the US health in the medical examination industry.†Jiang Xiaofeng said in an interview. At present, Mei Nian Da Health has built nearly 600 stores in 150 cities across the country. It was listed in 2015 and acquired “Mai Zhao†and “Ci Ming†in 2016 and 2017 respectively, becoming the market value and influence of the medical and health sectors. Outstanding listed company.
Both internal and external, and Xixi comprehensively layout the big health industry
Yuxi’s investment in the health industry is mainly in three major sectors:
It is a leading professional health checkup and medical service group in China. It is a core strategic partner of China.
Invested in the genetic testing industry, and established the National Genetic Monitoring Technology Demonstration Center - Xixi Medical Laboratory to provide health checkups and genetic testing services. Xixi International, a wholly-owned subsidiary in Australia, also collaborated with Monash University to build a laboratory. Through the joint laboratory, Professor Richard Boyd, a well-known professor of immunology at Monash University, and his team developed a personal immune system health screening. The system provides a comprehensive and meticulous assessment of the client's overall understanding of the state of the immune system. This technology has been put into use in Australia and will soon be launched in China through the Kunming Kunming Conversion Center.
Investing in stem cell industrialization research, Yuxi cooperated with Monash University to transfer its technology to Yunnan, and established the Yunnan Province Stem Cell Bank and the Yunnan Provincial Minority Sample Bank. In recent years, the State Health and Health Commission, the United Nations General Administration of Food and Drug Administration has issued a certificate for the registration of stem cell clinical research institutions for 102 top three hospitals. Xixi cooperated with many of the hospitals. Among them, the “Stem Cell Therapy Pulmonary Fiber†clinical research project with Zhongshan Hospital of Fudan University Affiliated Hospital passed the preliminary examination of the major special projects of the Ministry of Science and Technology in 2017, which became the major Specialized in one of two stem cell projects.
Yunnan Stem Cell Bank
Stem cell preparation
Yuxi started the global layout of Australia and the UK from 2012, established a wholly-owned subsidiary in Australia, Xixi International, signed a strategic partnership agreement with Monash University, and invested in the establishment of the Xixi-Monash immune regeneration and neuroscience experiments. room. At present, Xixi International cooperates with Professor Alan Trounson, the director of the Translation Research Center of Monash University, to study the transformation of stem cell remodeling immune system for cancer, CAR-T new generation technology for solid tumor treatment, and is expected to enter clinical trials in 2019. .
In addition, he participated in the UK's participation in the United States, and cooperated with Oxford University, the University of Wales, Loughborough University and other research and development of stem cell fully automated amplification technology.
"One-handed scientific research, first-hand industry landing, Xixi is trying to become the pathfinder of the industrialization of regenerative medicine," Jiang Xiaofeng said. "Our current clinical research results show that regenerative medicine will reshape the trajectory of life. Coupled with policy guidance, I believe that regenerative medicine will soon benefit the public and benefit everyone."
Sunshade Net,White Agriculture Shade Cloth,Air Filter Aluminum Foil Net,Fence Balcony Privacy Netting
Changzhou Green Nets Co.,Ltd. , https://www.gnshadenet.com